M Słomkowski

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD

Clifford R. Jack, M Słomkowski, S. Gracon et al. · Neurology · 2003 · 294 citations

VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY

Christopher H. van Dyck, Carl Sadowsky, Ghislaine Le Prince Leterme et al. · The Journal of Prevention of Alzheimer s Disease · 2016 · 30 citations

Neurodegenerative Diseases, Alzheimer's Disease, Vanutide Cridificar +5

The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia

A. Sikorska, M Słomkowski, Krystyna Maślanka et al. · Clinical & Laboratory Haematology · 2004 · 27 citations

Thrombopoiesis, Thrombosis, Translational Medicine +14

The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients

Andrzej B Szczepanik, A. Sikorska, M Słomkowski et al. · International Journal of Laboratory Hematology · 2007 · 20 citations

A placebo-controlled, double-blind study of pregabalin treatment of social phobia: Outcome and predictors of response

Douglas E. Feltner, Mark H. Pollack, J. Davidson et al. · European Neuropsychopharmacology · 2000 · 12 citations

Behavioral Sciences, Psychopathology, Behavioral Medicine +12